ESMO 2026 has ended. This guide stays up as the record of who was there. Next: ESMO 2027, Sep 17–21, 2027 in Barcelona

CI

Catalan Institute of Oncology (ICO) at ESMO 2026

Oct 23–27, 2026 Madrid, Spain ~37k attendees Website

Catalan Institute of Oncology (ICO) takes part in 16 sessions at ESMO 2026 in Madrid. Its work covers treatment choices and outcomes across several cancers, with attention to biomarkers and personalized care. It explores which patients with locally advanced rectal cancer may achieve a complete response and preserve the organ.

OrganizationESMO 2026 Attendance
CI
Catalan Institute of Oncology (ICO)
L'Hospitalet de Llobregat, Spain
Cancer centre & hospital
Public cancer centre of the Catalan health system, with its main hospital in L'Hospitalet de Llobregat near Barcelona, Spain.
Poster
Fri Oct 23
13:00–15:00
A phase 2, multicenter study of TILs treatment in germ cell tumors: The ARES study
ePoster session 6
Genitourinary cancersSarcoma, CNS, head & neck and rare cancers
Poster
Fri Oct 23
13:00–15:00
Dynamic GDF15 and systemic nutritional vulnerability in oropharyngeal cancer
ePoster session 8
Sarcoma, CNS, head & neck and rare cancersBiomarkers & precision oncology
Poster
Fri Oct 23
13:00–15:00
Poster
Fri Oct 23
13:00–15:00
Poster
Fri Oct 23
13:00–15:00
Transcriptomic dissection of metastatic uveal melanoma identifies survival-linked biological programs
ePoster session 11
Melanoma & skin cancersBiomarkers & precision oncology
Poster
Sat Oct 24
12:00–12:45
Cytoreductive surgery following tebentafusp (tebe) in metastatic uveal melanoma (mUM): A proof-of-concept case series with translational analysis
Saturday Poster Display session 4
Melanoma & skin cancersSarcoma, CNS, head & neck and rare cancers
Poster
Sat Oct 24
12:00–12:45
Phase I/II study of ICOVIR-5 with allogeneic mesenchymal stem cells (AloCelyvir) in metastatic uveal melanoma (PULSE-UM)
Saturday Poster Display session 4
Melanoma & skin cancersSarcoma, CNS, head & neck and rare cancers
Satellite
Sat Oct 24
13:35–14:05
Treatment evolution in mHSPC: Who needs treatment intensification?
Novartis - PSMA-targeted RLT in Prostate Cancer: Present and future
Genitourinary cancers
Talk
Sat Oct 24
16:00–16:15
Satellite
Sat Oct 24
18:30–18:35
Chair’s welcome and introductions
Boehringer Ingelheim International GmbH - HER2 and DLL3: Shaping the next generation of targeted cancer therapy
Lung & thoracic cancers
Satellite
Sat Oct 24
18:55–19:05
HER2 across cancers: Unlocking broader therapeutic potential
Boehringer Ingelheim International GmbH - HER2 and DLL3: Shaping the next generation of targeted cancer therapy
Lung & thoracic cancers
Satellite
Sat Oct 24
19:55–20:00
Chair’s closing remarks
Boehringer Ingelheim International GmbH - HER2 and DLL3: Shaping the next generation of targeted cancer therapy
Lung & thoracic cancers
Chair
Sun Oct 25
10:15–11:30
Evolving treatment paradigms in nasopharyngeal carcinoma
with National Cancer Centre Singapore
Sarcoma, CNS, head & neck and rare cancers
Talk
Sun Oct 25
10:15–10:20
Presentation of case/condition
Evolving treatment paradigms in nasopharyngeal carcinoma
Sarcoma, CNS, head & neck and rare cancers
Poster
Sun Oct 25
12:00–12:45
Abstract
Sun Oct 25
14:45–14:50
Chair
Sun Oct 25
14:45–16:15
Rapid oral: Head and neck cancer
with The Chinese University of Hong Kong, Humanitas Research Hospital
Sarcoma, CNS, head & neck and rare cancers
Abstract
Sun Oct 25
15:54–16:06
Invited Discussant LBA47, 1538RO and 1541RO
Rapid oral: Head and neck cancer
Sarcoma, CNS, head & neck and rare cancers
Poster
Mon Oct 26
12:00–12:45
Long-term outcomes and prognostic factors in conventional chondrosarcoma: A single reference-center cohort
Monday Poster Display session 6
Sarcoma, CNS, head & neck and rare cancers
Poster
Mon Oct 26
12:00–12:45

Explore the full ESMO 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Madrid. Leave your work email and we’ll be in touch.

Privacy

Download the full ESMO 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at Catalan Institute of Oncology (ICO)

Tell us what you sell and we’ll find the people at Catalan Institute of Oncology (ICO) most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction